6-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Form 6-K/A

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2024

Commission File Number: 001-41641

SHL TELEMEDICINE LTD.

 (Translation of registrant’s name into English)

90 Yigal Alon Street

Tel Aviv 67891, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒             Form 40-F ☐

EXPLANATORY NOTE

On March 14, 2024, SHL Telemedicine Ltd. (the “Company”) filed a Form 6-K (the “Original Form 6-K”) in which it disclosed that it had issued a press release, a copy of which was furnished as Exhibit 99.1 thereto. In the press release, the Company announced that Erez Nachtomy, the Company’s CEO, would be resigning in mid-June 2024 and that the Board of Directors of the Company would shortly commence a search (both internally and externally) for a new CEO.

The Company is filing this Form 6-K/A to amend the Original Form 6-K and disclose that the search for a new CEO is progressing, and at the request of the Board of Directors Mr. Nachtomy has agreed to remain as the CEO until the end of August 2024.

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 9, 2023 (Registration No. 333-272546).

Exhibit	Description
99.1	Press release, dated June 25, 2024, issued by the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SHL Telemedicine Ltd.

By: /s/ Amir Hai

      Amir Hai

      Chief Financial Officer

June 25, 2024

EX-99.1

Exhibit 99.1

Press release

SHL Telemedicine provides an update regarding CEO position

Tel Aviv / Zurich / New York, June 25, 2024 - SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today that further to the press release issued by the Company dated March 14, 2024 regarding change in CEO position,  the search for a new CEO is progressing, and at the request of the Board of Directors Mr. Nachtomy has agreed to remain as the CEO until the end of August 2024.

About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal telemedicine systvaems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).

For more information, please visit our website at www.shl-telemedicine.com.

Contacts

Fabienne Farner, IRF, Phone : +41 43 244 81 42, farner@irf-reputation.ch

Forward-Looking Statements
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.